Boehringer and SBP Group Sign $7B Cancer Drug Deal
Ingelheim, Germany, and Hong Kong, China, November 4, 2026 Boehringer Ingelheim and Sino Biopharmaceutical Limited (SBP Group) have entered...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Ingelheim, Germany, and Hong Kong, China, November 4, 2026 Boehringer Ingelheim and Sino Biopharmaceutical Limited (SBP Group) have entered...
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
